Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial

REFERENCES

• Bica I, McGovern B, Dhar R, et al. Increasing mortal-ity due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001 ;32(3):492–497.
   PubMed Web of Science ®Google Scholar
• Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3): 272–279.
   PubMed Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25(2)171–180.
   Web of Science ®Google Scholar
• Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coin-fected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–413.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55(5):728–736.
   PubMed Web of Science ®Google Scholar
• Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16(5):352–358.
   PubMed Web of Science ®Google Scholar
• Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis. 2003;36(1):97–100.
   PubMed Web of Science ®Google Scholar
• Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis. 2003;36(8):1039–1046.
   PubMed Web of Science ®Google Scholar
• Taylor LE, Costello T, Alt E, Yates G, Tashima K. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS. 2002;16(12):1700–1701.
   PubMed Web of Science ®Google Scholar
• Loftis JM, Hauser P. The phenomenology and treat-ment of interferon-induced depression. J Affect Disord. 2004;82(2)1 75–190.
   Web of Science ®Google Scholar
• Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4): 731–746.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: Author; 2013.
   Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treat-ment of hepatitis C infection. N Engl J Med. 2009;361(6): 580–593.
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1): S237–244.
   PubMed Web of Science ®Google Scholar
• Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Viler FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treat-ment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7)1 051–1055.
   Web of Science ®Google Scholar
• Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136–139.
   PubMed Web of Science ®Google Scholar
• Loftis JM, Hauser P. Safety of the treatment of inter-feron-alpha-induced depression. Psychosomatics. 2003;44(6):524–526.
   PubMed Web of Science ®Google Scholar
• Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–966.
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Rifai MA, Lofts JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent inter-feron-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103(1-3):83–90.
   PubMed Web of Science ®Google Scholar
• Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163–1174.
   PubMed Web of Science ®Google Scholar
• Diez-Quevedo C, Masnou H, Planes R, et al. Prophylac-tic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: A 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(4):522–528.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depres-sion in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial. Ann Intern Med. 2012;157(2):94–103.
   PubMed Web of Science ®Google Scholar
• Klein MB, Cooper C, Brouillette MJ, et al. CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29(4):617–30.
   PubMed Web of Science ®Google Scholar
• PEGETRON (ribavirin + peginterferon alfa-2b) [product monograph]. Merck & Co, Inc. December 17,2012.
   Google Scholar
• Gheorghe L, Lacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointest Liver Dis. 2007;16(1):23–29.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with inter-feron alfa and ribavirin in psychiatric risk groups. Hepatol-ogy. 2003;37(2):443–451.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology.2002;123(4):1061–1069.
   PubMed Web of Science ®Google Scholar
• Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S143–151.
   PubMed Web of Science ®Google Scholar
• Beck A, Steer R, Brown G. BDI-II Manual. 2nd ed. New York: Psychological Corporation; 1996.
   Google Scholar
• Demyttenaere K, De Fruyt J. Getting what you ask for: On the selectivity of depression rating scales. Psychother Psychosom. 2003;72(2):61–70.
   PubMed Web of Science ®Google Scholar
• Castellon SA, Hinkin CH, Wood S, Yarema KT. Apathy, depression, and cognitive performance in HIV-1 infection. J Neuropsychiatry Clin Neuroscl. 1998;10(3): 320–329.
   PubMed Web of Science ®Google Scholar
• Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry. 1999;60(11):741–746.
   PubMed Web of Science ®Google Scholar
• Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospec-tive study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44(2): 104–112.
   PubMed Web of Science ®Google Scholar
• Widiger T. DSM-IV Sourcebook. Arlington, VA: American Psychiatric Association; 1994.
   Google Scholar
• First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
   Google Scholar
• Udina M, Castellvi P, Moreno-Espana J, et al. Inter-feron-induced depression in chronic hepatitis C: A sys-tematic review and meta-analysis. J Clin Psychiatry. 2012;73(8)1128–1138.
   Web of Science ®Google Scholar
• Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: Estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005 ;61(7):835–854.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: A Euro-pean expert consensus statement. J Hepatol. 2012;57(6): 1379–1390.
   PubMed Web of Science ®Google Scholar
• Hou X-J, Xu J-H, Wang J, Yu Y-Y. Can antidepressants prevent pegylated interferon-a/ribavirin-associated depression in patients with chronic hepatitis C: Meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One. 2013;8(10):e76799.
   Google Scholar